David Ricks, Eli Lilly CEO (David Paul Morris/Bloomberg via Getty Images)

Eli Lil­ly an­tic­i­pates rev­enue boost in 2023 as it pre­pares to launch slate of new drugs

Eli Lil­ly ex­ec­u­tives are bull­ish on its prospects for next year as the In­di­anapo­lis phar­ma lifts the cov­er on its 2023 fi­nan­cial guid­ance.

Rev­enues are ex­pect­ed to land be­tween $30.3 bil­lion and $30.8 bil­lion next year, Lil­ly said on Tues­day, a bump over its ex­pect­ed 2022 rev­enue be­tween $28.5 bil­lion and $29 bil­lion as re­port­ed in the third quar­ter. Lil­ly at­trib­uted the 2023 gains to “vol­ume-based rev­enue growth” for ex­ist­ing prod­ucts, along with up to four pos­si­ble launch­es for do­nanemab, pir­to­bru­ti­nib, le­brik­izum­ab and mirik­izum­ab. Among those, key Phase III read­outs are ex­pect­ed for do­nanemab in ear­ly Alzheimer’s and mirik­izum­ab in Crohn’s dis­ease.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.